Last reviewed · How we verify
High Dose Inactivated Influenza Vaccine
A high-dose inactivated influenza vaccine stimulates a stronger immune response by delivering increased antigen content to enhance antibody production and cellular immunity against influenza viruses.
A high-dose inactivated influenza vaccine stimulates a stronger immune response by delivering increased antigen content to enhance antibody production and cellular immunity against influenza viruses. Used for Influenza prevention in adults aged 65 years and older, Influenza prevention in immunocompromised populations.
At a glance
| Generic name | High Dose Inactivated Influenza Vaccine |
|---|---|
| Sponsor | University of Pittsburgh |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles at higher antigen concentrations than standard-dose vaccines, which triggers more robust activation of B cells and T cells. This enhanced immunogenicity is intended to provide superior protection against influenza infection, particularly in older adults and immunocompromised populations who may have diminished responses to standard-dose vaccines.
Approved indications
- Influenza prevention in adults aged 65 years and older
- Influenza prevention in immunocompromised populations
Common side effects
- Injection site soreness
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age (PHASE3)
- Clinical Trials of Quadrivalent Influenza Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: